BioCentury
ARTICLE | Clinical News

Synta slides on updated ganetespib data

October 29, 2013 12:46 AM UTC

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) fell $1.30 (20%) to $5.10 on Monday after reporting updated data from the Phase IIb/III GALAXY-1 trial evaluating ganetespib (formerly STA-9090) as second-line treatment for advanced, metastatic non-small cell lung cancer (NSCLC). The data came from 178 stage IIIB/IV NSCLC adenocarcinoma patients who were enrolled more than six months after diagnosis of disease -- the population Synta chose for Phase III testing.

In the updated data, ganetespib plus docetaxel led to a median overall survival (OS) of 10.7 months vs. 7.4 months for docetaxel alone at one-year of follow-up in the subgroup (unadjusted HR=0.75, p=0.065). In June, Synta reported that ganetespib plus docetaxel led to a median OS of 10.7 months vs. 6.4 months for docetaxel alone after six months of follow-up in the subgroup (unadjusted HR=0.61, p=0.0093). Synta also said trial sites in Russia and Ukraine enrolled healthier patients compared to other study sites, and that patients in the docetaxel arm had a median treatment duration of 8.3 months in Russia and Ukraine vs. 2.8 months for patients enrolled elsewhere. Synta presented the data at the World Conference on Lung Cancer in Sydney. ...